Evidence map›Paper›PMID 39702584›Full record

Observational studyBritish journal of cancer2025

The accuracy of fluorine 18-labelled prostate-specific membrane antigen PET/CT and MRI for diagnosis of prostate cancer in PSA grey zone.

Liang Luo, Ruiyan Wang, Lu Bai, Jin Shang, Xinyi Wang, Ruxi Chang, Weixuan Dong, Yang Li, Yan Li, Hua Liang and 2 more

Registry-linked trialAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in British journal of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05958004 (Application Value of Biopsy Free Technique for Prostate Specific Antigen Grey Area Prostate Cancer Based on 18F-Prostate Specific Membrane Antigen-1007 Positron Emission Tomography/Computerized Tomography), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05958004 completednot on this map

Application Value of Biopsy Free Technique for Prostate Specific Antigen Grey Area Prostate Cancer Based on 18F-Prostate Specific Membrane Antigen-1007 Positron Emission Tomography/Computerized Tomography

TypeobservationalSponsorFirst Affiliated Hospital Xi'an Jiaotong UniversityRan2023 to 2024Enrolled92ConditionsProstatic Neoplasms
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. The value of [Quantitative imaging in medicine and surgery · 2026
    Article
  2. Diagnostic value of [Frontiers in oncology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Liang LuoPET/CT Center, The First Affiliated Hospital of Xi' an Jiaotong University, Xi' an, China.
Ruiyan WangPET/CT Center, The First Affiliated Hospital of Xi' an Jiaotong University, Xi' an, China.
Lu BaiDepartment of Radiology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi' an, China.
Jin ShangDepartment of Radiology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi' an, China.
Xinyi WangState Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, China.
Ruxi ChangPET/CT Center, The First Affiliated Hospital of Xi' an Jiaotong University, Xi' an, China.
Weixuan DongPET/CT Center, The First Affiliated Hospital of Xi' an Jiaotong University, Xi' an, China.
Yang LiPET/CT Center, The First Affiliated Hospital of Xi' an Jiaotong University, Xi' an, China.
Yan LiPET/CT Center, The First Affiliated Hospital of Xi' an Jiaotong University, Xi' an, China.
Hua LiangDepartment of Pathology, The First Affiliated Hospital of Xi' an Jiaotong University, Xi' an, China.
Hongjun XieDepartment of Urology, The First Affiliated Hospital of Xi' an Jiaotong University, Xi' an, China. xiehongjun0@163.com.
Xiaoyi DuanPET/CT Center, The First Affiliated Hospital of Xi' an Jiaotong University, Xi' an, China. duanxyi@yeah.net.ORCID http://orcid.org/0000-0003-0473-862X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe diagnostic utility of prostate biopsy is limited for prostate cancer (PCa) in the prostate-specific antigen (PSA) grey zone. This study aims to evaluate the diagnostic performance of multiparametric magnetic resonance imaging (mpMRI) and prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) for PSA grey zone PCa and clinically significant PCa (csPCa).

methodsA total of 82 patients with PSA levels ranging from 4 to 10 ng/mL who underwent

results

conclusionsCLINICAL

trial registrationNCT05958004, 2024-07.

Indexed as

Magnetic Resonance ImagingPositron Emission Tomography Computed TomographyProstate-Specific AntigenProstatic NeoplasmsAgedAged, 80 and overAntigens, SurfaceFluorine RadioisotopesGlutamate Carboxypeptidase IIHumansMaleMiddle AgedMultiparametric Magnetic Resonance ImagingNiacinamideOligopeptidesProspective StudiesAntigens, SurfaceFluorine-18Fluorine RadioisotopesFOLH1 protein, humanGlutamate Carboxypeptidase IINiacinamideOligopeptidesProstate-Specific AntigenPSMA-1007

Identifiers

PMID39702584
PMCPMC11791168

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.